Navigation Links
High Cost of Biologics and Novel Oral Agents to Treat Immune Diseases Limits Patient Access
Date:12/10/2013

BURLINGTON, Mass., Dec. 10, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the high cost per patient per year of biologics and novel oral therapies for the treatment of rheumatoid arthritis (RA) and psoriasis often results in reimbursement hurdles that limit patients' ability to access these therapies. Among RA patients in the United States who are eligible but do not receive a biologic/novel oral therapy (approximately 10 percent of disease-modifying antirheumatic [DMARD]-treated RA patients), more than 35 percent do not receive treatment because of cost-related issues, and approximately 20 percent do not receive treatment because of payer restrictions.

The new Strategic Insights report entitled Trends in Reimbursement for Immune Biologics: Strategies for Success also finds that in an attempt to control the increasing costs associated with biologics/novel oral agents, particularly the non-TNF-alpha inhibitors, payers frequently use a wide range of strategies and tactics such as prior authorization, step-therapy requirements and blocking copay assistance programs for nonpreferred agents.

"As new biologics/novel oral agents and biosimilars enter the RA and psoriasis markets, drug marketers can expect more payer scrutiny and restrictions," said Decision Resources Analyst Adi Reske, Ph.D. "Payers will demand extensive data and greater discounts and rebates to justify giving a therapy preferred coverage. To overcome the increasing barriers, drug marketers must employ different strategies including more cost-effective agents, head-to-head clinical data, and greater discounts and rebates."

About Strategic Insights
Strategic Insights is a new series of high-level, strategic reports from Decision Resources Group thought leaders, designed for corporate executives in the biopharma industry. The Strategic Insights series evaluates global industry trends that are shaping the healthcare market, and delivers targeted, actionable insight in an easy-to-read PowerPoint format.

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Althea Technologies Appoints Dr. Kristin DeFife, Director, Biologics Manufacturing And Jack Wright, VP, Sales and Marketing
2. Synthetic Biologics Appoints Carol Reed, M.D., as Senior Vice President of Clinical & Regulatory Affairs
3. Avaxia Biologics is Awarded U.S. Patent for Method to Treat Radiation Damage to the Digestive Tract and Mucositis Caused by Radiation
4. CSL Behring Announces FDA Filing of Biologics License Application for 4-Factor PCC for Urgent Reversal of Vitamin K Antagonist Anticoagulant Therapy
5. Avaxia Biologics Announces Appointment of Michael D. Rivard as VP Corporate Development
6. Chinese Compulsory Immunization Program for Livestock Creates Massive Opportunity for Animal Vaccines and Biologics Developers
7. CMC Biologics Achieves Successful Pre-Approval European GMP Inspection by MHRA for Commercial Manufacturing
8. Pinnacle Biologics and INTERmedic Medical Devices announce strategic manufacturing and distribution agreement for cancer laser technology
9. CMC Biologics Acquires XOMAs Bay Area Manufacturing Facility
10. Global Spinal Devices and Biologics Market 2011-2015
11. Synthetic Biologics Reports Second Quarter 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... June 24, 2016   Pulmatrix, Inc ., (NASDAQ: ... innovative inhaled drugs, announced today that it was added ... reconstituted its comprehensive set of U.S. and global ... is an important milestone for Pulmatrix," said Chief Executive ... awareness of our progress in developing drugs for crucial ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... report to their offering. ... kidney failure, it replaces the function of kidneys by removing ... thus the treatment helps to keep the patient body,s electrolytes ... Increasing number of ESRD patients & substantial healthcare expenditure ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: RO, ... clearance for its Elecsys BRAHMS PCT (procalcitonin) assay as ... or septic shock. With this clearance, Roche is the ... fully integrated solution for sepsis risk assessment and management. ... bacterial infection and PCT levels in blood can aid ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... 24, 2016 , ... Southern Illinois University School of Dental ... Illinois State Dental Society (ISDS) Foundation’s Mission of Mercy (MOM). They will host ... Collinsville. , They expect to treat approximately 2,000 patients from Illinois, ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... a not-for-profit organization responsible for clinical transfusion research programs and for the blood ... Pathogen Reduction Evaluation and Predictive Analytical Rating Score (PREPAReS) study. , Currently ...
(Date:6/23/2016)... ... June 23, 2016 , ... SyncDog, Inc. , ... security software, is featured in the current issue of Silicon Review ... with innovative technology solutions and features them in their magazine. The magazine allows ...
(Date:6/23/2016)... ... 23, 2016 , ... Horizon Blue Cross Blue Shield of ... from the crushing burden of sky-high health care costs, Superior Court of New ... ( http://www.judiciary.state.nj.us/opinions/a2913-15a2929-15.pdf ) the court provided some analysis of the contracts between ...
(Date:6/23/2016)... ... ... A key metric of this success is the popularity of the Leafedin.org service ... areas that lack the kind of technology and networking framework that LeafedIn.org provide, where ... the marijuana industry, no matter how small or large, and more importantly no matter ...
Breaking Medicine News(10 mins):